logo/base Created with Sketch.

FibroScan®-based Score: Fast™

Fast™是识别高风险NASH患者的最佳即时医疗综合测试

wave

Fast™目标

目前,NASH药物研发主要针对有进展为肝硬化风险的NASH患者,或是由显性纤维化NASH(NASH+NAS≥4+F≥2)界定的代偿期肝硬化患者。

Fast™说明

Fast™将FibroScan®检查结果(采用LSM by VCTE™ & CAP™)与易于获取的血液生物标志物(AST)相结合,有助于在即时医疗场所识别显性纤维化NASH患者,减少侵入性及昂贵的检查。

Fast™性能

在衍生队列以及来自不同临床环境(NAFLD三级护理单元、筛查、减肥手术)和地理来源(美国、欧洲、亚洲)的外部验证队列中表现良好乃至优秀。
已有若干文献提倡使用Fast™。

Fast™:久经考验,值得信赖

quote

Fast™的改进与NASH关键组织学特征的改善一致,包括炎症和纤维化。

Boursier等人发表的意见 | Oral ILC(EASL)2020:摘要AS075

quote

Fast™评分在我们的队列中表现出对纤维化NASH的良好识别能力。

Anand等人发表的意见。 | European Journal of Gastroenterology & Hepatology期刊,2020年

chevron chevron

Fast™ calculator is a tool for clinicians, computed from LSM and CAP (obtained from FibroScan® device) and AST blood parameter measurement, to aid in the identification of a patient with suspicion of NAFLD as being at risk for active fibrotic NASH (NASH+NAS≥4+F≥2). It was developed based on a prospective multicenter cohort and published in peer-reviewed literature. Fast™ is presented as an educational service intended for licensed healthcare professionals. While this score is about specific medical and health issues, it is not a substitute for or a replacement of personalized medical advice and is not intended to be used as the sole basis for making individualized medical or health-related decisions.